RHAPSIDO is NOW APPROVED for symptomatic | View the Data |
CSU patient portrayal.
RHAPSIDO: a first-of-its-kind* oral targeted therapy for CSU1
When antihistamines aren't enough for chronic spontaneous urticaria (CSU), cut to RHAPSIDO.1
*Bruton's tyrosine kinase inhibitor indicated for CSU.1
†Multiple imputation techniques were implemented for missing data.1
‡Limitations apply. Subject to annual co-pay benefit limit. Offer not valid under Medicare, Medicaid, or any other federal or state programs. Novartis reserves the right to rescind, revoke, or amend this program without notice. Additional limitations may apply. See complete Terms & Conditions at rhapsido.com for details.
†Multiple imputation techniques were implemented for missing data.1
‡Limitations apply. Subject to annual co-pay benefit limit. Offer not valid under Medicare, Medicaid, or any other federal or state programs. Novartis reserves the right to rescind, revoke, or amend this program without notice. Additional limitations may apply. See complete Terms & Conditions at rhapsido.com for details.